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Sn¼156). Red cell distribution width (RDW), neutrophile-lymphocyte ratio (NLR) and
peak high sensitive C-reactive protein (hs-CRP) levels were measured. We also
evaluated in hospital clinical course of the patients.
Results: RDW, NLR and peak hs-CRP levels were signiﬁcantly lower in patients with
lead endocarditis when compared with non-lead endocarditis (14,8  1,6 versus 16,7
 3,1, p¼0,01, 2,9  1,07 versus 7,4  7, p¼0,01 and 22,4  31,3 versus 58,6  69,
p¼0,03 respectively). In hospital mortality was similar in two groups (11.7% versus
30.1%, p¼0.11). Ejection fraction was lower in the group with lead endocarditis
(49,7% 14,4 versus 55,6%  9.8, p¼0.03) however, clinical congestive heart failure
was more common in the non-lead endocarditis group (28,2% versus 5,8%, p¼0.004).
Conclusıon: In hospital mortality was similar in patients with lead and non-lead left
sided endocarditis. Inﬂammatory markers such as RDW, NLR and hs-CRP were lower
in lead endocarditis. Additionally despite of lower ejection, clinical congestive heart
failure development was less in lead endocarditis which all should alert physicians that
lead endocarditis might have more silent course and might be omitted.
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Introductıon: After its introduction by Jatene and colleagues in 1975, the arterial
switch operation (ASO) has become the surgical technique of choice for correction of
transposition of the great arteries (TGA) with or without ventricular septal defect
(VSD). Short- and mid-term results are promising, but data on long-term outcome are
limited and major complications may occur.
Objectıves: Our work is intended to assess the long term results of ASO in Tunisian
children with TGA and to identify potential factors affecting these results.
Methods: We studied 44 patients with ASO (mean age: 11.5 years, 73%-male, 50 %
TGA with VSD) followed at our department. The inclusion criterion was at least 5
years of follow-up. Complete clinical examination, standard and 24-hour Holter
electrocardiogram, M-mode, 2D-and color Doppler echocardiography and coronary
investigations were performed.
Results: Mean follow-up was 106 months (8.83 years). One patient died (2.27%).
Impaired left ventricular function was observed in 5 cases (11.36%). Right ventricular
outﬂow tract obstruction was observed in 6 patients (13.63%) requiring reintervention
in 2 cases. Pulmonary regurgitation was frequent (40.90%). Aortic regurgitation was
observed in 20 patients (45.45%) but appeared not to be progressive. Coronary lesions
were found in 4 patients (9.09%) requiring a coronary artery bypass graft (CABG) in 1
case. Intramural coronary artery course was the risk factor of late coronary arteries
lesions (p¼0.013) Freedom from late reintervention was 84% at 15 years after ASO.
Eight late reinterventions were performed in 4 patients (9.09%) with a mean age of
10.43 years.
Conclusıon: The TGA, including complex types, can be corrected with good long-
term outcomes by ASO. The association to a VSD was not considered to be
a predictor of long-term complications except of aortic regurgitation. Right ventricular
outﬂow tract dysfunction was the main reason for late reinterventions. Potential risk of
myocardial ischemia requires regular appropriate follow up.
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and Triglyceride in Men
Loreta Bica Bica1, Mimoza Lezha Lezha2, Neki Kuka Kuka3, Artan Goda Goda2
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Background: Low HDL cholesterol (HDL-C) levels are now recognized as an
independent cardiovascular risk factor and comprise part of the metabolic syndrome.
Low testosterone (T) levels are a common ﬁnding in men with coronary artery disease.
Methods: The relationship between endogenous plasma testosterone and high-density
lipoprotein cholesterol (HDL-C) was assessed among 933 men (27-74) years old
originally recruited for an cross-sectional study of endogenous testosterone and
coronary artery disease (CAD). Patients underwent coronarygraphy and at the same
time, serial testosterone was measured, triglycerides, total-and HDL-cholesterol.
Results: Patients (coronary narrowing >50% n ¼ 689) were compared to those
without signiﬁcant stenoses (n ¼ 244). High-density lipoprotein cholesterol (HDLC)
and triglyceride were both signiﬁcantly associated with the presence of CAD
(p<0.05). Testosterone (mean 5.5682.109 nmol/l range 0.106 – 14.108 nmol/l)JACC Vol 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTcorrelated directly with HDL-cholesterol (r¼0. 0.358, < P¼0.0500) and inversely
with triglycerides (r¼-0.069, p<0.0010),but not with LDL-cholesterol (r¼0.140,
p¼0.1990) total cholesterol (r¼-0.036, p<0.820),
Conclusıons: These ﬁndings suggest the positive association between levels of
testosterone and HDL cholesterol, The negative association between levels of
testosterone triglyceride.
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Background: Low circulating levels of high density lipoprotein-cholesterol (HDL-C)
is the most common form of dyslipidemia in coronary heart disease (CHD). In
previous studies, it has been shown that low circulating levels of HDL-C is a strong,
independent risk factor for premature atherosclerosis and CHD. Plasma HDL-C
particles exert potent anti-atherogenic and anti-inﬂammatory activities in addition to
antioxidant activity. Thus, we aimed to investigate biochemical parameters associated
with oxidative stress stress in low HDL-C.
Method: This study included 33 consecutive patients with low HDL-C (35 mg/dl)
(18 male, age 5513 years) and 33 age and sex-matched control subjects with normal
HDL-C (>35 mg/dl) (17 male, mean age 5813 years). We evaluated clinical
parameters and laboratory parameters which are associated with oxidative stress such as
total oxidative status (TOS), total antioxidant capacity (TAC), oxidative stress index
(OSI), uric asit, gamma glutamyl transferase (GGT) and alkaline phosphatase (ALP).
Results: Groups were comparable in demographic and clinic characteristics. Except
for ALT levels routine laboratory tests were similar in both groups. ALT levels was
higher in low HDL-C patients than in subjects with normal HDL-C (2919 vs 185.3
mg/dl, p<0.01). Triglyceride (TG) levels were higher in low HDL-C group, total
cholesterol (TK) and low density lipoprotein (LDL) levels were signiﬁcantly higher in
control group. HDL-C levels was lower in patients group than in control group (303
vs 487 mg/dl, p<0.01). Uric asit (6.31.5 vs 4.51.3, respectively p<0.01) and
GGT levels [35 (10-122) vs 23 (11-71.6), p¼0.02] were signiﬁcantly higher in low
HDL-C group than in control group. TOS levels were signiﬁcantly higher in low
HDL-C group than in control group [2.95 (0.01-7.26) vs 1.17 (0.80-1.80), p<0.01],
TAC levels were signiﬁcantly lower in low HDL-C group than in control group [1.15
(0.08-2.25) vs 1.99 (0.42-6.21), p<0.01]. OSI levels [474 (1.19-5050) vs 176 (28-
597), p¼0.06] were slightly higher in HDL-C group although it is not signiﬁcant.
Conclusıon: Our ﬁndings show that oxidative stress levels increase in patients with low
HDL-C. From this aspect, treatments that increase HDL levels or improve the antioxi-
dant status in low HDL-C patients might be reasonable to slow down the process of
oxidative stress. However, this result needs to be validated in large-sized studies.
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Purpose: Catestatin (CST), a novel peptide derived from Chromogranin A, has
diverse cardiovascular actions in addition to diminished sympathoadrenal ﬂow. We
intended to investigate metabolic and vascular associations of CST.
Methods: We evaluated plasma catestatin, lipid parameters, left ventricular mass,
carotid intima-media thickness (CIMT) and ﬂow-mediated dilation (FMD) of brachial
artery in a group of 109 consecutive untreated hypertensive patients.
Results: Catestatin levels were signiﬁcantly higher in females. Among all study
parameters age (r¼0.280, p¼0.001), high density lipoprotein (HDL) (r¼0.426,
p<0.001) positively whereas triglycerides (r¼-0.317, p¼0.002), hemoglobin (r¼-
0.273, p¼0.010), and left ventricular mass (r¼-0.230, p¼0.034) negatively correlated
to plasma catestatin. We could not detect an association between vascular parameters
and catestatin. We also documented increased CST concentrations in previously
untreated hypertensive patients compared to healthy controls (2.27 vs. 1.92 ng/ml,
p¼0.004). Multiple linear regression analysis revealed age (Beta: 0.201, p¼0.041) and
HDL cholesterol (Beta: 0.390, p<0.001) as independent correlates of plasma cate-
statin concentration.
Conclusıon:We documented that catestatin is correlated with high density lipoprotein
concentrations among several metabolic, vascular and biochemical parameters, in
previously untreated hypertensive patients. The physiology and clinical signiﬁcance of
this association remains unknown and requires further studies to be identiﬁed.ERS C181
Linear regression analyses were used for prediction of plasma catestatin
levels
Linear
regression
analysis
Dependent
variable: Plasma
catestatin level
Beta
(standardized) yP value
Beta
(standardized)
Independent
variables *P value
Age, years 0.006 0.277 0.041 0.201
Gender,
male
0.381 -0.133
HDL, mg/dL 0.381 -0.133 <0.001 0.390
Triglycerides,
mg/dL
0.381 -0.179
Hemoglobin
(mg/dL)
0.837 -0.028
Left
ventricular
mass (g)
0.189 -0.147
Constant 0.055 - 0.737 -
Adjusted R2 0.268 0.202
Linear regression analysis with enter method was used for all relevant independent variables
which were included if they were signiﬁcantly different in the univariate analyses*. In addition
the analysis was repeated after a pre-elimination with Stepwise method for the independent
variablesy.
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Evaluation of Dose Efﬁcacy of Treatment with Atorvastatin, Rosuvastatin And
Simvastatin in Patients with Hyperlipidemia
Orhan Demir, Serdar Sevimli, Hüsnü Degirmenci, Hakan Duman,
Eftal Murat Bakırcı, Selami Demirelli, Hikmet Hamur
Department of Cardiology, Faculty of Medicine, Ataturk University, Erzurum
Objectıve: Atherosclerotic heart diseases continue to be the most important cause of
death in developed countries. Hyperlipidemia is the most crucial risk factor inC182 JACC Voatherosclerosis development. The statins used in hyperlipidemia treatment play an
essential role in reducing the morbidity and mortality associated with atherosclerosis.
There are numerous studies on old generation statins and new generation statins;
however, there are limited number of studies comparing these two groups. Therefore,
we aimed to present this study to the literature and determine the dose efﬁcacy of
hypolipidemic agents by comparing the old generation statin simvastatin to new
generation statins (atorvastatin, rosuvastatin).
Methods: This study is a clinical, prospective cohort study. A total of 160 subjects (76
women and 84 men) who applied to our clinic from November 2011 to May 2011 and
were indicated for medicinal treatment according to National Cholesterol Education
Programme Adult Treatment Panel (NCEP ATP) 3 criteria despite the four week long
ﬁrst line diet were included in the study. Following the evaluation of lipid proﬁles
based on medical history, physical examination, and clinical and laboratory ﬁndings,
eligible subjects were assigned to the three groups according to simvastatin dose (10
mg, 20 mg, 40 mg/day), three groups according to atorvastatin dose (10 mg, 20 mg, 40
mg/day) two groups according to rosuvastatin dose (10 mg, 20 mg/day). Thus, a total
of 8 groups were generated. There were 20 patients in each group. In our study, the
subjects were evaluated with clinical and laboratory methods at baseline and after 6
weeks of treatment.
Results: The mean age of the 160 patients enrolled for the study was 58.9510.22 (37
to 82). There was no difference between the groups with regards to demographic
characteristics. The reduction in low-density lipoprotein (LDL) cholesterol was 28-
40% (10-40 mg/day) with simvastatin, 39-51% (10-40 mg/day) with atorvastatin and
50-60% (10-20 mg/day) with rosuvastatin after 6 weeks of treatment (p<0.01). The
increase in high-density lipoprotein (HDL) cholesterol at week 6 compared to baseline
was most prominent in the rosuvastatin (20 mg/day) group.
Conclusıon: We detected that the hypolipidemic effects of rosuvastatin and ator-
vastatin were more prominent compared to simvastatin. This supports the idea that
new generation statins may be used in clinical practice to a further extent compared to
old generation statins. Furthermore, based on the ﬁndings of our study it can be
concluded that rosuvastatin may be the preferred choice of treatment in hyperlipidemia
patients with low levels of HDL-C.
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Myocardial Infarction and Death Following Receipt of Clavis Panax
Serhat Karadavut1, Ömer S¸ahin2, Mehmet Güngör Kaya1
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Coronary artery disease (CAD) is a chronic process that begins early in life and
progresses silently before becoming symptomatic. Besides scientiﬁcally based medical
treatment of this disease, patients frequently make use of alternative medicine. The
product sold as Clavis Panax that used by many people as a food supplements
according to the advertisements. Intake of a mixture of plant extracts may have serious
consequences in humans as drug interactions and side effects are unknown. Herein,
we report the case of a 58-year-old man who presented with chest pain. Due to typical
symptoms a coronary angiography and stent implantation was performed to the critical
lesions at the left anterior descending artery and right coronary artery successfully.
Initially his LDL level was 87 mg/dL, total cholesterol level was 154 mg/dL and
triglyceride level was 165 mg/dL. Three months later after he was discharged, he gave
up his medication and started to take an herbal drug called Clavis Panax. At the sixth
month after stent implantation, his LDL level was 224 mg/dL, total cholesterol was
388 mg/dL and triglyceride was 365 mg/dL. He was warned to stop taking Clavis and
was prescribed an increased dose of statin but he refused. He died of a myocardial
infarction in the eighth month after stent implantation.
PP-248
Effects of CoQ10 Supplementation on Serum Lipoprotein, Il-6, ICAM-1 and
Plasma Fibrinogen in Hyperlipidemic Patients with Myocardial Infarction
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Abbas Rahimi2
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Because,dyslipidemia,inﬂammation and hypercoagulation are the major risk factors
for cardiovascular diseases we examined the Effects of CoQ10 supplementation on
serum lipoprotein, Il-6, ICAM-1 and plasma ﬁbrinogen in hyperlipidemic patients
with myocard infarction. In a double blind placebo controled clinical trial, 52
hyperlipidemic patients with myocard infarction and age range of 35-70 years were
randomly allocated to receive daily 200 mg coQ10 or placebo for 3 months. Fasting
blood, Physical activity and daily dietary intake were obtained at beginning and end of
3 months. SPSS version 18 were used for statistical analysis. At the end of study in
CoQ10 group,There were signiﬁcant decrease in total cholesterol (TC), Triglyceride
(TG), LDL-c, LDL-c/HDL-c and TC/HDL-c (p<0.05), IL-6 (p<0.001) and ICAM-1
(p<0.001) and signiﬁcant increase in HDL-c (p<0.05) compare to beginning of study.
At the end of study there were signiﬁcant decrease in LDL-c/HDL-c (p<0.05), TC/
HDL-c (p<0.05), IL-6 (p<0.001), ICAM-1 (P<0.001) and signiﬁcant increase in
HDL-c (p<0.05) compare to placebo group.We can conclude that 200 mg daily
CoQ10 for 3 months may have favorite effects on serum lipoproteins and inﬂam-
mation indicators but no effect on ﬁbrinogen and may be beneﬁcal in myocardial
infarction patients.l 62/18/Suppl C j October 26–29, 2013 j TSC Abstracts/POSTERS
